ALK and non-small cell lung carcinoma: A retrospective study of biomarker analyses across 15 US community oncology sites for patients with non-squamous NSCLC diagnosed between January 1, 2013 and December 31, 2015 revealed that only 59% of tumors had undergone genomic testing for EGFR and ALK, the two most well-established biomarkers, in accordance with the CAP/IASLC/AMP guidelines (24).